Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials
about
Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyondSAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?Un-sweetening the Heart: Possible pleiotropic effects of SGLT2 inhibitors on cardio and cerebrovascular alterations in resistant hypertensive subjects.Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
P2860
Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Cardiovascular safety of empag ...... ized placebo-controlled trials
@ast
Cardiovascular safety of empag ...... ized placebo-controlled trials
@en
type
label
Cardiovascular safety of empag ...... ized placebo-controlled trials
@ast
Cardiovascular safety of empag ...... ized placebo-controlled trials
@en
prefLabel
Cardiovascular safety of empag ...... ized placebo-controlled trials
@ast
Cardiovascular safety of empag ...... ized placebo-controlled trials
@en
P2093
P2860
P356
P1476
Cardiovascular safety of empag ...... ized placebo-controlled trials
@en
P2093
P2860
P304
P356
10.1111/DOM.12734
P577
2016-07-04T00:00:00Z